Clinical Trials Logo
  1. Home
  2. Oropharynx Cancer
  3. NCT04444869

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer — ENID  

Oropharynx Cancer Clinical Trial

Official title:
Phase II Trial of Definitive Chemoradiation With Elective Nodal Irradiation Dose De-escalation for p16 Positive Squamous Cell Carcinoma of the Oropharynx "ENID"

Clinical Trial Summary

This trial will explore giving standard dose chemotherapy and radiation therapy to sites of disease including all lymph nodes involved with HPV-positive oropharyngeal cancer, but administer lower doses of radiation therapy to the lymph nodes that are not known to be involved with cancer. By doing so, it is hypothesized that there will be equally good long term loco-regional and distant disease control but will reduced long term treatment side effects and improved quality of life in persons living well beyond their cancer treatment.

Clinical Trial Description

This is a trial of definitive chemotherapy and radiation therapy in human papilloma virus positive oropharyngeal cancers, in a population whose cancer is thought to be highly radio-sensitive. This is a population whose outcomes are already known to be very good with high rates of local and distant control of the disease. With the long term disease control and survival of patients with this disease, long term treatment toxicity and resulting reduction in quality of life poses new problems. This has lead to several studies to examine the role of radiation dose de-escalation through various strategies in attempt to reduce long term toxicity from treatment and yet achieve equivalent long term disease control. This trial specifically hypothesizes that a lower dose of radiation therapy to the clinically and radiographically uninvolved lymph nodes will no detrimental effect on loco-regional control or overall survival and will improve the long-term side effect profile, particularly with regards to xerostomia and dysphagia. The goal of this study is therefore to determine whether a lower dose to the clinically and radiographically uninvolved lymph nodes can be done safely and with better long-term toxicity profile and better overall quality of life without compromising the expected outcomes of progression free survival. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04444869
Study type Interventional
Source University of Missouri-Columbia
Contact Gregory Biedermann, MD
Phone (573) 884-8264
Email biedermanng@health.missouri.edu
Status Recruiting
Phase Phase 2
Start date September 28, 2020
Completion date June 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT00158678 - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Phase 3
Completed NCT04567082 - Proteome- and Methylation Profiles in Oropharyngeal Cancer
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Completed NCT03435471 - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer N/A
Completed NCT05055206 - Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers N/A
Recruiting NCT04359199 - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Active, not recruiting NCT02908477 - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Phase 3
Active, not recruiting NCT00232960 - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC N/A
Completed NCT05698667 - Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer N/A
Recruiting NCT05757817 - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Completed NCT03342378 - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Active, not recruiting NCT03416153 - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer Phase 2
Terminated NCT01066741 - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Phase 3
Completed NCT03418792 - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx N/A
Recruiting NCT06088381 - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Phase 2
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2